Evogene
Open
$0.58
Prev. Close
$0.58
High
$0.58
Low
$0.58
Market Snapshot
$4.88M
-0.4
-2.85
$5.58M
52
Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. The company is headquartered in Rehovot, Central(Hamerkaz) and currently employs 142 full-time employees. The company went IPO on 2007-06-11. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. The company is headquartered in Rehovot, Central(Hamerkaz) and currently employs 142 full-time employees. The company went IPO on 2007-06-11. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
Recently from Cashu
Evogene Navigates Financial Challenges by Focusing on AI and Strategic Industry Partnerships
Evogene Ltd (Ticker: EVGN) focuses on leveraging its proprietary AI technology to enhance its operations and product offerings. In its recent financial results for the first quarter of 2026, the compa…
Evogene Showcases ChemPass AI™ at BIO International Convention 2026 to Advance Drug Development
Evogene Ltd. (Ticker: EVGN) is positioning itself prominently within the biotechnology and pharmaceutical landscapes through its participation in the upcoming BIO International Convention in San Diego…
Evogene Advances BMC128 Therapy in Phase 1 Study for Advanced Solid Tumors
Evogene Ltd. (Ticker: EVGN) announces a significant advancement in its clinical research with the successful completion of a Phase 1 study for BMC128, a microbiome therapy developed by its subsidiary,…
Evogene Unveils AI Innovations at BIO-Europe Spring 2026 Conference in Lisbon
Evogene Showcases AI-Driven Innovations at BIO-Europe Spring 2026 Conference Evogene Ltd., a leader in computational chemistry, prepares to showcase its cutting-edge advancements in AI-driven small-mo…